Loading stock data…
ALMS
$23.66+2.24 (+8.65%)
Market ClosedLast close May 11
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Alumis Inc. in the Healthcare sector is trading at $23.66. The stock is currently 23% below its 52-week high of $30.60, remaining 65.9% above its 200-day moving average. Technical signals show neutral RSI of 43 and bearish MACD signal, explaining why ALMS maintains its current momentum and trend strength. The Whystock Score of 75/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 43) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$23.66
Potential Upside
5%
Whystock Fair Value$24.84
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus10 analysts
Mean target$38.40+62.3%
Range$25.00 – $55.00
Fundamentals
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psori...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$3.58B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-86.68%
Volume
Today's trading volume
942,974
Recent News
Why One Fund’s $4 Million Alumis Buy Looks Like a Bet on a Breakthrough Autoimmune Drug
Alumis develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases with a focus on TYK2 inhibition technology.
Personalis (PSNL) Reports Q1 Loss, Tops Revenue Estimates
Personalis (PSNL) delivered earnings and revenue surprises of -26.09% and +7.56%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Raymond James and Guggenheim Stay Bullish on Alumis (ALMS) After Trial Results
Alumis Inc. (NASDAQ:ALMS) is one of the 10 Best Performing Stocks of Q1 2026 to Watch for Q2. On March 30, Raymond James reaffirmed its Strong Buy rating on Alumis Inc. (NASDAQ:ALMS) with a price target of $46 after the company presented Phase 3 trial data at the American Academy of Dermatology meeting. Raymond James […]
Why Alumis (ALMS) Is Down 5.8% After Positive Phase 3 Psoriasis Data And NDA Plans
Alumis Inc. recently reported past Phase 3 ONWARD1 and ONWARD2 trial results showing envudeucitinib, its oral TYK2 inhibitor, delivered high skin clearance, rapid itch relief, and quality-of-life gains for adults with moderate-to-severe plaque psoriasis, with a generally well-tolerated safety profile through Week 24. A key insight is envudeucitinib’s ability to sustain strong 24-hour TYK2 inhibition while minimizing off-target effects, positioning it as a differentiated oral option for...
Alumis (ALMS) Valuation Check After Positive Phase 3 Psoriasis Results For Envudeucitinib
What Alumis’ Phase 3 psoriasis data means for ALMS stock Alumis (ALMS) has put envudeucitinib at the center of the story after releasing Phase 3 ONWARD1 and ONWARD2 data in moderate to severe plaque psoriasis, alongside plans to seek FDA approval this year. For you as an investor, this is a clinically focused event with direct relevance for how the market may view Alumis’ pipeline, risk profile, and potential future revenue sources if envudeucitinib reaches the market. See our latest analysis...